Predicting ovarian activity in women affected by early breast cancer: Ameta-analysis-based nomogram

Agnese Barnabei, Lidia Strigari, Paolo Marchetti, Valentina Sini, Liana De Vecchis, Salvatore Maria Corsello, Francesco Torino

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background. The assessment of ovarian reserve in premenopausal women requiring anticancer gonadotoxic therapy can help clinicians address some challenging issues, including the probability of future pregnancies after the end of treatment. Anti-Müllerian hormone (AMH) and age can reliably estimate ovarian reserve. A limited number of studies have evaluated AMH and age as predictors of residual ovarian reserve following cytotoxic chemotherapy in breast cancer patients. Materials and Methods. To conduct a meta-analysis of published data on this topic, we searched the medical literature using the key MeSH terms “amenorrhea/chemically induced,” “ovarian reserve,” “anti-Mullerian hormone/blood,” and “breast neoplasms/drug therapy.” Preferred Reporting Items for Systematic Reviews and Meta-Analyses statements guided the search strategy. U.K. National Health Service guidelines were used in abstracting data and assessing data quality and validity. Area under the receiver operating characteristic curve (ROC/AUC) analysis was used to evaluate the predictive utility of baseline AMH and age model. Results. The meta-analysis of data pooled from the selected studies showed that both age and serum AMH are reliable predictors of post-treatment ovarian activity in breast cancer patients. Importantly, ROC/AUC analysis indicated AMH was a more reliable predictor of post-treatment ovarian activity in patients aged younger than 40 years (0.753; 95% confidence interval [CI]: 0.602–0.904) compared with those older than 40 years (0.678; 95% CI: 0.491–0.866). We generated a nomogram describing the correlations among age, pretreatment AMH serum levels, and ovarian activity at 1 year from the end of chemotherapy. Conclusion. After the ongoing validation process, the proposed nomogram may help clinicians discern premenopausal women requiring cytotoxic chemotherapy who should be considered high priority for fertility preservation counseling and procedures.

Original languageEnglish
Pages (from-to)1111-1118
Number of pages8
JournalThe oncologist
Volume20
Issue number10
DOIs
Publication statusPublished - Sep 4 2015

Fingerprint

Nomograms
Hormones
Breast Neoplasms
ROC Curve
Meta-Analysis
Drug Therapy
Area Under Curve
Confidence Intervals
Fertility Preservation
Anti-Mullerian Hormone
Amenorrhea
National Health Programs
Therapeutics
Serum
Counseling
Guidelines
Pregnancy
Ovarian Reserve

Keywords

  • Anti-Müllerian hormone
  • Breast cancer
  • Ovarian reserve
  • Ovarian toxicity
  • Predictive factors

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Barnabei, A., Strigari, L., Marchetti, P., Sini, V., Vecchis, L. D., Corsello, S. M., & Torino, F. (2015). Predicting ovarian activity in women affected by early breast cancer: Ameta-analysis-based nomogram. The oncologist, 20(10), 1111-1118. https://doi.org/10.1634/theoncologist.2015-0183

Predicting ovarian activity in women affected by early breast cancer : Ameta-analysis-based nomogram. / Barnabei, Agnese; Strigari, Lidia; Marchetti, Paolo; Sini, Valentina; Vecchis, Liana De; Corsello, Salvatore Maria; Torino, Francesco.

In: The oncologist, Vol. 20, No. 10, 04.09.2015, p. 1111-1118.

Research output: Contribution to journalArticle

Barnabei, A, Strigari, L, Marchetti, P, Sini, V, Vecchis, LD, Corsello, SM & Torino, F 2015, 'Predicting ovarian activity in women affected by early breast cancer: Ameta-analysis-based nomogram', The oncologist, vol. 20, no. 10, pp. 1111-1118. https://doi.org/10.1634/theoncologist.2015-0183
Barnabei, Agnese ; Strigari, Lidia ; Marchetti, Paolo ; Sini, Valentina ; Vecchis, Liana De ; Corsello, Salvatore Maria ; Torino, Francesco. / Predicting ovarian activity in women affected by early breast cancer : Ameta-analysis-based nomogram. In: The oncologist. 2015 ; Vol. 20, No. 10. pp. 1111-1118.
@article{3b3611c4528d4c3db26540c7357e7e44,
title = "Predicting ovarian activity in women affected by early breast cancer: Ameta-analysis-based nomogram",
abstract = "Background. The assessment of ovarian reserve in premenopausal women requiring anticancer gonadotoxic therapy can help clinicians address some challenging issues, including the probability of future pregnancies after the end of treatment. Anti-M{\"u}llerian hormone (AMH) and age can reliably estimate ovarian reserve. A limited number of studies have evaluated AMH and age as predictors of residual ovarian reserve following cytotoxic chemotherapy in breast cancer patients. Materials and Methods. To conduct a meta-analysis of published data on this topic, we searched the medical literature using the key MeSH terms “amenorrhea/chemically induced,” “ovarian reserve,” “anti-Mullerian hormone/blood,” and “breast neoplasms/drug therapy.” Preferred Reporting Items for Systematic Reviews and Meta-Analyses statements guided the search strategy. U.K. National Health Service guidelines were used in abstracting data and assessing data quality and validity. Area under the receiver operating characteristic curve (ROC/AUC) analysis was used to evaluate the predictive utility of baseline AMH and age model. Results. The meta-analysis of data pooled from the selected studies showed that both age and serum AMH are reliable predictors of post-treatment ovarian activity in breast cancer patients. Importantly, ROC/AUC analysis indicated AMH was a more reliable predictor of post-treatment ovarian activity in patients aged younger than 40 years (0.753; 95{\%} confidence interval [CI]: 0.602–0.904) compared with those older than 40 years (0.678; 95{\%} CI: 0.491–0.866). We generated a nomogram describing the correlations among age, pretreatment AMH serum levels, and ovarian activity at 1 year from the end of chemotherapy. Conclusion. After the ongoing validation process, the proposed nomogram may help clinicians discern premenopausal women requiring cytotoxic chemotherapy who should be considered high priority for fertility preservation counseling and procedures.",
keywords = "Anti-M{\"u}llerian hormone, Breast cancer, Ovarian reserve, Ovarian toxicity, Predictive factors",
author = "Agnese Barnabei and Lidia Strigari and Paolo Marchetti and Valentina Sini and Vecchis, {Liana De} and Corsello, {Salvatore Maria} and Francesco Torino",
year = "2015",
month = "9",
day = "4",
doi = "10.1634/theoncologist.2015-0183",
language = "English",
volume = "20",
pages = "1111--1118",
journal = "Oncologist",
issn = "1083-7159",
publisher = "Wiley Blackwell",
number = "10",

}

TY - JOUR

T1 - Predicting ovarian activity in women affected by early breast cancer

T2 - Ameta-analysis-based nomogram

AU - Barnabei, Agnese

AU - Strigari, Lidia

AU - Marchetti, Paolo

AU - Sini, Valentina

AU - Vecchis, Liana De

AU - Corsello, Salvatore Maria

AU - Torino, Francesco

PY - 2015/9/4

Y1 - 2015/9/4

N2 - Background. The assessment of ovarian reserve in premenopausal women requiring anticancer gonadotoxic therapy can help clinicians address some challenging issues, including the probability of future pregnancies after the end of treatment. Anti-Müllerian hormone (AMH) and age can reliably estimate ovarian reserve. A limited number of studies have evaluated AMH and age as predictors of residual ovarian reserve following cytotoxic chemotherapy in breast cancer patients. Materials and Methods. To conduct a meta-analysis of published data on this topic, we searched the medical literature using the key MeSH terms “amenorrhea/chemically induced,” “ovarian reserve,” “anti-Mullerian hormone/blood,” and “breast neoplasms/drug therapy.” Preferred Reporting Items for Systematic Reviews and Meta-Analyses statements guided the search strategy. U.K. National Health Service guidelines were used in abstracting data and assessing data quality and validity. Area under the receiver operating characteristic curve (ROC/AUC) analysis was used to evaluate the predictive utility of baseline AMH and age model. Results. The meta-analysis of data pooled from the selected studies showed that both age and serum AMH are reliable predictors of post-treatment ovarian activity in breast cancer patients. Importantly, ROC/AUC analysis indicated AMH was a more reliable predictor of post-treatment ovarian activity in patients aged younger than 40 years (0.753; 95% confidence interval [CI]: 0.602–0.904) compared with those older than 40 years (0.678; 95% CI: 0.491–0.866). We generated a nomogram describing the correlations among age, pretreatment AMH serum levels, and ovarian activity at 1 year from the end of chemotherapy. Conclusion. After the ongoing validation process, the proposed nomogram may help clinicians discern premenopausal women requiring cytotoxic chemotherapy who should be considered high priority for fertility preservation counseling and procedures.

AB - Background. The assessment of ovarian reserve in premenopausal women requiring anticancer gonadotoxic therapy can help clinicians address some challenging issues, including the probability of future pregnancies after the end of treatment. Anti-Müllerian hormone (AMH) and age can reliably estimate ovarian reserve. A limited number of studies have evaluated AMH and age as predictors of residual ovarian reserve following cytotoxic chemotherapy in breast cancer patients. Materials and Methods. To conduct a meta-analysis of published data on this topic, we searched the medical literature using the key MeSH terms “amenorrhea/chemically induced,” “ovarian reserve,” “anti-Mullerian hormone/blood,” and “breast neoplasms/drug therapy.” Preferred Reporting Items for Systematic Reviews and Meta-Analyses statements guided the search strategy. U.K. National Health Service guidelines were used in abstracting data and assessing data quality and validity. Area under the receiver operating characteristic curve (ROC/AUC) analysis was used to evaluate the predictive utility of baseline AMH and age model. Results. The meta-analysis of data pooled from the selected studies showed that both age and serum AMH are reliable predictors of post-treatment ovarian activity in breast cancer patients. Importantly, ROC/AUC analysis indicated AMH was a more reliable predictor of post-treatment ovarian activity in patients aged younger than 40 years (0.753; 95% confidence interval [CI]: 0.602–0.904) compared with those older than 40 years (0.678; 95% CI: 0.491–0.866). We generated a nomogram describing the correlations among age, pretreatment AMH serum levels, and ovarian activity at 1 year from the end of chemotherapy. Conclusion. After the ongoing validation process, the proposed nomogram may help clinicians discern premenopausal women requiring cytotoxic chemotherapy who should be considered high priority for fertility preservation counseling and procedures.

KW - Anti-Müllerian hormone

KW - Breast cancer

KW - Ovarian reserve

KW - Ovarian toxicity

KW - Predictive factors

UR - http://www.scopus.com/inward/record.url?scp=84943249191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943249191&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2015-0183

DO - 10.1634/theoncologist.2015-0183

M3 - Article

AN - SCOPUS:84943249191

VL - 20

SP - 1111

EP - 1118

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 10

ER -